Nephrology & Urology

Kidneys, dialysis, stones, infections, prostate, and continence concerns.

  • 5 Tracked terms
  • Last 30 days Feed window

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Nephrology & Urology


hcplive.com > view > fibrillary-gn-cardiovascular-protection-and-recurrence-after-kidney-transplant

Fibrillary GN: Cardiovascular Protection and Recurrence After Kidney Transplant

51+ min ago   (308+ words) Gerald Appel, MD, opens the segment by highlighting an added benefit of nonspecific therapy in fibrillary glomerulonephritis (FGN). Beyond reducing proteinuria, agents such as ACE inhibitors, angiotensin receptor blockers, and certain antidiabetic drugs also lower cardiovascular risk, including stroke and…...


timesnowhindi.com > bizz-impact > diabetes-bp-obesity-are-your-kidneys-at-risk-video-156283905

Diabetes, BP & Obesity: Are Your Kidneys at Risk? | Dr. Modi

9+ hour, 42+ min ago   (38+ words) Updated Oct 6, 2026, 14:12 IST Can Kidney Damage Be Slowed? New Treatments Offer Hope | Dr. Avinash Dialysis Myths Busted: Is Dialysis Always Permanent? 3 Pillars for Healthy Kidneys CKD: Why Early Screening Can Save Your Kidneys...


prnewswire.com > news-releases > nkf-innovation-fund-invests-in-nephrogen-to-advance-one-time-gene-editing-therapies-for-kidney-disease-302899875.html

NKF Innovation Fund Invests in Nephrogen to Advance One-Time Gene Editing Therapies for Kidney Disease

4+ hour, 36+ min ago   (195+ words) Oct 06, 2026, 09:45 ET Investment supports advancement of a delivery platform built to solve the barrier that has kept genetic medicines out of the kidney, and a lead program in polycystic kidney disease. NEW YORK, Oct. 6, 2026 /PRNewswire/ -- The National Kidney Foundation (NKF)…...


citizen.co.za > highway-mail > news-headlines > local-news > 10/06/2026 > durban-survivor-urges-men-to-screen-for-prostate-cancer

Durban survivor urges men to screen for prostate cancer

4+ hour, 42+ min ago   (295+ words) According to GLOBOCAN, prostate cancer is now the most prevalent cancer in SA men and the second most deadly after lung cancer. One in four Black men and one in eight white men will be diagnosed in their lifetime. Also…...


medscape.com > viewarticle > arpis-tied-equal-pfs-benefits-metastatic-prostate-cancer-2026a10011ei

ARPIs Tied to Equal PFS Benefits in Metastatic Prostate Cancer

3+ hour, 41+ min ago   (335+ words) ARPIs Tied to Equal PFS Benefits in Prostate Cancer Medscape ARPIs Tied to Equal PFS Benefits in Metastatic Prostate Cancer ARPIs — abiraterone, apalutamide, and enzalutamide — combined with androgen-deprivation therapy (ADT) were associated with longer progression-free survival vs docetaxel plus ADT…...


nature.com > articles > s41416-026-03633-5

Clinical significance of circulating macrophage markers across different stages of prostate cancer: highlighting soluble CD163

14+ hour, 24+ min ago   (1690+ words) British Journal of Cancer (2026) Cite this article The clinical significance of circulating macrophage markers in prostate cancer (PC) is largely unexplored. Here, we hypothesised that serum levels of the macrophage markers CD163 and SIRPα might be associated with disease aggressiveness and…...


globenewswire.com > news-release > 10/06/2026 > 3375435 > 37519 > en > akebia-therapeutics-announces-late-breaking-voice-trial-presentation-and-posters-on-akebia-s-rare-kidney-pipeline-at-asn-kidney-week-2026.html

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

6+ hour, 24+ min ago   (483+ words) October 06, 2026 08:00 ET | Source: Akebia Therapeutics, Inc. Akebia Therapeutics, Inc. ASN Kidney Week attendees can visit Akebia at Booth #682 in the Exhibit Hall. Late-breaking presentation by U.S. Renal Care details: Vadadustat Three Times Weekly for the Treatment of Anemia in Patients Receiving…...


aol.com > articles > prostate-cancer-foundation-honors-mary-123000000.html

Prostate Cancer Foundation Honors Mary-Ellen Taplin, MD, with the 2026 PCF Women in Science Lifetime Achievement Award

5+ hour, 52+ min ago   (121+ words) Dr. Taplin receives 2026 PCF Women in Science Lifetime Achievement Award The award recognizes women who have demonstrated extraordinary scientific achievement, leadership, and a lifelong commitment to advancing prostate cancer research and patient care. Dr. Taplin was selected through a process…...